


339 F.3d 1373
United States Court of Appeals,
Federal Circuit.
SCHERING CORPORATION, Plaintiff-Appellant,
v.
GENEVA PHARMACEUTICALS, INC. and Novartis Corporation, and Teva Pharmaceuticals USA, Inc., and Andrx Corporation, Andrx Pharmaceuticals LLC, and Andrx Pharmaceuticals, Inc., and Mylan Pharmaceuticals, Inc., and Wyeth, ESI-Lederle, Wyeth Pharmaceuticals, and Wyeth Consumer Healthcare (formerly American Home Products Corporation, Wyeth-Ayerst Laboratories, and Whitehall Robbins Healthcare), and Impax Laboratories, Inc., Apotex, Inc. and Novex Pharma, Copley Pharmaceutical, Inc., and Genpharm, Inc., Defendants-Appellees.
Nos. 02-1540, 02-1541, 02-1542, 02-1543, 02-1544, 02-1545, 02-1546, 02-1547, 02-1548, 02-1549, 03-1021, 03-1022, 03-1023, 03-1025, 03-1027.
|
Aug. 1, 2003.
Synopsis
Owner of patent for antihistamine metabolite sued manufacturers of generic versions for infringement. The United States District Court for the District of New Jersey, 2002 WL 2001552, John W. Bissell, Chief Judge, held that patent was invalid, and appeal was taken. The Court of Appeals, Rader, Circuit Judge, held that patent was inherently anticipated by prior art patent for underlying antihistamine.
 
Affirmed.
 
